Actively Recruiting
Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
Led by Baycrest · Updated on 2024-08-13
42
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
Sponsors
B
Baycrest
Lead Sponsor
A
Alzheimer's Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
CONDITIONS
Official Title
Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Mild to moderate Alzheimer's Disease
- Score between 18 and 25 on the Montreal Cognitive Assessment (MoCA)
- Score on the Cambridge Naming Task during the pre-assessment
You will not qualify if you...
- History of stroke or traumatic brain injury (TBI)
- Presence of shunts or metal implants in the body
- History of significant heart disease, alcoholism, or drug use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Baycrest Health Sciences
Toronto, Ontario, Canada, M6A 2E1
Actively Recruiting
Research Team
C
Carlos Roncero, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here